PQE-GROUP
25.6.2024 17:21:35 CEST | Business Wire | Press release
PQE Group, a leading consultancy in the Life Science sector, announces the consolidation of its new Regulated Artificial Intelligence & Data Analytics division operating since the initiation of AI based tools in the industrial space. This marks a pivotal step in the company's evolution, positioning the Italian Group, comprised of more than 2000 employees, at the forefront of technological innovation in Life Sciences. The new division is designed to enhance business process efficiency and effectiveness while ensuring regulatory compliance. Leveraging advanced technologies, PQE Group offers services like AI-driven decision optimization, risk reduction, and accelerated innovation, all adhering to industry regulations. The 2024 Stanford Report on AI highlighted AI's significant role in accelerating scientific discovery in 2022, with further strengthening in 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625598895/en/
Danilo Neri - Partner & Vice President Executive at PQE Group (Photo: PQE Group)
“Regulators have started addressing the expectations for these solutions, but there is still much to do, since regulated companies need detailed guidance on documentation required to ensure explainability and performance of each tool," emphasized Danilo Neri, Partner & Vice President Executive of PQE Group. "Just a few weeks ago, the final approval of the AI Act in the European Union was granted, representing the world's most advanced regulation on artificial intelligence, requiring documentation to address explainability. It is an important step, but it is equally important that penalties are effectively applied to offenders to not compromise consumer, worker, and citizen protection at the expense of innovation and market competitiveness. The full establishment of this division will allow us to consolidate our position as a leader in the sector, offering exceptional compliance approaches and tailor-made solutions to our clients that meet regulatory expectations and the increasingly complex market needs." PQE Group’s dedicated validation approach has been designed to meet the current regulatory expectations for machine learning-based tools and for Generative AI solutions.
PQE Group's partnership with the Canadian company GenAIz will further boost service capacity. GenAIz, focused on the use of AI for supporting humanity, has developed a platform to speed up decision-making and execution with better business insights. This collaboration will enhance PQE Group's ability to offer innovative solutions and the necessary validation packages required by GxP regulations and by incoming industry wide rules (e.g., European AI act). Led by Catherine Lunardi, CEO of GenAIz and a spokesperson at the G7 on AI and wellbeing, GenAIz's AI platform will leverage PQE Group's global presence, which includes more than 45 offices worldwide.
The Regulated Artificial Intelligence & Data Analytics division will be presented in a panel discussion and networking event in Rockville, MD, on July 17, 2024. Experts will discuss AI regulations and the future of life sciences, marking a significant innovation for the pharmaceutical and medical device industry.
The press and readers are warmly invited to the event.
Please confirm attendance and find more information by registering here: https://hubs.ly/Q02CMQrj0
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625598895/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-severe Atopic Dermatitis16.3.2026 11:53:00 CET | Press release
Almirall announces positive, top-line results from Phase 3 ADorable-1 trialADorable-1 met co-primary efficacy endpoints, with 63% of paediatric patients achieving meaningful skin improvement (EASI-75) and 44% reaching clear or almost clear skin (IGA 0,1) at week 16.Key secondary endpoints showed significant itch relief (Pruritus NRS ≥4 point improvement), reduced overall disease severity (EASI-90) and improved quality of life (CDLQI ≥6-Point Improvement) in children and adolescents with moderate-to-severe atopic dermatitis treated with lebrikizumab.Skin conditions can have a profound physical and emotional impact on people’s lives1, and Atopic Dermatitis (AD) peaks in childhood – with around 60% of cases appearing within the first year of life2. Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line results from the pivotal Phase 3 ADorable-1 trial evaluating efficacy and safety of lebrikizumab for children and adoles
Experian Marks a Breakthrough in Consumer AI with the Next Evolution of Its Virtual Assistant16.3.2026 11:00:00 CET | Press release
Smarter, more adaptive assistant advances personalized, conversational financial guidance powered by trusted data Experian today unveiled the next evolution of the Experian Virtual Assistant, EVA™, a significant advancement in its Consumer First AI strategy that expands personalized, conversational financial guidance to millions of consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316538160/en/ Experian today unveiled the next evolution of the Experian Virtual Assistant, EVA™. “This next generation of EVA reflects the direction of our consumer AI strategy,” said Debbie Hsu, Executive Vice President of Product, Experian Consumer Services. “We are bringing together conversational AI, personalization, and our trusted data foundation to deliver guidance that is intuitive, relevant, and actionable. Our focus is on helping consumers make smarter financial decisions in ways that feel simple and empowering.” Built to scal
Triton Partners Successfully Closes Fund 6 at €5.5 Billion Target16.3.2026 08:00:00 CET | Press release
Triton Partners today announces the successful close of its sixth flagship mid-market fund (“T6” or “the Fund”) on target at €5.5 billion, the largest fund to date for Triton. The Fund has raised capital from new and existing investors globally, underscoring the continued confidence of Limited Partners in Triton’s European mid-market strategy and the Firm’s ability to build better businesses. Triton’s Mid-Market buyout (TMM) strategy focuses on its core sectors of industrial technology, business services and healthcare. As a responsible owner of choice, T6 will invest where its market and investment insights provide an edge, positioning the firm to capitalise on attractive opportunities, supported by the Accelerator Unit, Europe’s largest value creation team. T6 seeks to maintain the strong performance of previous funds, all having achieved top quartile returns. Reflecting this consistent track record, Triton was recently named as one of three European managers in the HEC global univer
Syngenta deepens research capabilities with QuantumBasel partnership16.3.2026 08:00:00 CET | Press release
At the World Agri-Tech Innovation Summit, Syngenta, a global leader in agricultural innovation, today announced it is exploring how quantum computing can help farmers meet the growing demands of food production in a changing climate. The company has partnered with QuantumBasel, Switzerland's first commercial quantum computing hub, to apply quantum technologies to agricultural research and development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316646014/en/ Ion trap, which uses electromagnetic fields to confine and control ions for use as quantum bits (qubits). Farmers worldwide face mounting pressure to produce more food sustainably amid unpredictable weather and evolving pest and disease challenges. Meeting these demands requires new scientific approaches that go beyond what classical computing can deliver, particularly when it comes to understanding the complex molecular and biological systems that underpin crop sc
NTT DATA Launches GCC Innovation Acceleration Program to Support Innovation Creation by Global Companies16.3.2026 04:30:00 CET | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced the launch of its GCC Innovation Acceleration Program. This is designed to support global companies rapidly establishing and scaling their strategic offshore hubs in India, including Global Capability Centers (GCC) and other innovation and delivery hubs. Launched in October 2025, the program aims to support more than 50 companies over the next three years. The demand for highly skilled IT personnel has expanded globally, and as a result, companies are increasingly using overseas bases to meet innovation needs. NTT DATA identified India as a stand-out market to launch the GCC Innovation Acceleration Program because of its abundance of talent and strong technical capabilities. India’s Global Capability Center ecosystem, delivering IT services and back-office functions to multinationals, is poised for strong growth of nearly 70%, targeting $110 billion in 2030 from the current $65 billion, according
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom